Vistagen reports positive fasedienol open-label extension data
Vistagen said preliminary open-label extension data showed fasedienol was well-tolerated and associated with clinically relevant improvement in social anxiety over four months.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Vistagen reports preliminary positive OLE data for fasedienol in SAD
Preliminary PALISADE-4 open-label extension data for fasedienol nasal spray suggest it was well-tolerated up to 12 months, with exploratory improvements on LSAS and SPIN over four months. Company plans to meet the FDA to consider a new registrational Phase 3.
Vistagen reports preliminary positive open-label extension data for fasedienol
Vistagen said fasedienol nasal spray was well-tolerated in social anxiety disorder patients, with no new drug-related safety findings after as-needed use for up to 12 months. The company reported clinically relevant improvements over time on clinician- and patient-reported scales during the open-label extension portion